Gilgamesh

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for mental health disorders. Founded in 2019, the company aims to address the global mental health crisis by creating new chemical entities (NCEs) that leverage the therapeutic benefits of psychedelics. Gilgamesh utilizes an AI-powered platform to accelerate and optimize the development of these compounds, ensuring improved safety, tolerability, duration, and efficacy.

History of Gilgamesh

Since its inception, Gilgamesh has achieved several significant milestones. In March 2024, the company announced a $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a cardiac-safe ibogaine analogue for the treatment of opioid use disorder. This funding supports toxicology studies and Phase 1/1b clinical trials. Additionally, Gilgamesh initiated a Phase 2a trial for GM-1020 in major depressive disorder in May 2024, aiming to assess this novel NMDA receptor antagonist’s safety, tolerability, and efficacy.

In May 2024, Gilgamesh entered a collaboration and option-to-license agreement with AbbVie to develop next-generation neuroplastogens for psychiatric disorders. This partnership combines AbbVie’s expertise in psychiatry with Gilgamesh’s innovative research platform.

The company’s founders include experts with extensive experience in academia and the pharmaceutical industry. Jonathan Sporn, Andrew Kruegel, and Dalibor Sames bring together a wealth of neuroscience, medicinal chemistry, and drug development knowledge. Their combined efforts have positioned Gilgamesh as a pioneering force in the field of mental health therapeutics.

Gilgamesh Pharmaceuticals continues to advance its therapeutic pipeline with the goal of fundamentally reshaping the treatment of mental illnesses such as depression, anxiety, and substance use disorders.